Curative Treatment for High-Grade Intraepithelial Neoplasia in Barrett’s Esophagus

 

 Buy Article Permissions and Reprints

Background and Study Aims: The incidence of premalignant and malignant lesions in specialized intestinal metaplasia of the esophagus has increased dramatically in the industrialized world in recent years. This report evaluates the efficacy and safety of local endoscopic therapy for high-grade intraepithelial neoplasia (HGIN) in Barrett’s esophagus.
Patients and Methods: Over a 5-year period between October 1996 and September 2001, a total of 379 patients were referred with a suspicion of early Barrett’s cancer. In a prospective study, 44 patients with HGIN in Barrett’s esophagus were selected for local endoscopic treatment. Endoscopic resection was carried out in 14 patients in whom the HGIN was re-detectable, and 27 patients in whom the HGIN was not re-detectable underwent photodynamic therapy (PDT). Endoscopic resection and PDT were combined in three patients.
Results: Complete remission was achieved in 43 of the 44 patients (97.7 %). No major complications occurred. A mean of 1 session was needed to achieve complete local remission. During a mean follow-up period of 36 months (range 7 - 61 months), recurrent or metachronous lesions were observed in six patients (17.1 %), all of whom received a second successful endoscopic treatment.
Conclusions: Endoscopic therapy is a safe alternative treatment regimen for HGIN in Barrett’s esophagus, providing a middle way between the widely promulgated options of a ”watch-and-wait” policy and radical esophagectomy.

References

• 1 Bytzer P, Christensen P B, Damkier P. et al . Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study.  Am J Gastroenterol. 1999;  94 86-91
  CrossrefPubMedGoogle Scholar
• 2 Heitmiller R F, Redmond M, Hamilton S R. Barrett’s esophagus with high-grade dysplasia: an indication for prophylactic esophagectomy.  Ann Surg. 1996;  224 66-71
  CrossrefPubMedGoogle Scholar
• 3 Stein H J, Feith M, Mueller J. et al . Limited resection for early adenocarcinoma in Barrett’s esophagus.  Ann Surg. 2000;  232 733-742
  CrossrefPubMedGoogle Scholar
• 4 Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The Practice Parameters Committee of the American College of Gastroenterology.  Am J Gastroenterol. 1998;  93 1028-1032
  CrossrefPubMedGoogle Scholar
• 5 The Society for Surgery of the Alimentary Tract (SSAT), American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE) Consensus Panel . Management of Barrett’s esophagus.  J Gastrointest Surg. 2000;  4 115-116
  CrossrefPubMedGoogle Scholar
• 6 Pech O, Nagy C D, Gossner L. et al . Photodynamic therapy of human Barrett’s cancer using 5-aminolaevulinic acid-induced protoporphyrin IX: an in-vivo dosimetry study in athymic nude mice.  Eur J Gatroenterol Hepatol.. 2002;  14 657-662
  CrossrefPubMedGoogle Scholar
• 7 Ell C, May A, Wurster H. The first reusable multiple-band ligator for endoscopic hemostasis of variceal bleeding, nonvariceal bleeding and mucosal resection.  Endoscopy. 1999;  31 738-740
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 May A, Gossner L, Behrens A. et al . A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus.  Gastrointest Endosc. 2003;  58 167-175
  CrossrefPubMedGoogle Scholar
• 9 Gossner L, Stolte M, Sroka R. et al . Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid.  Gastroenterology. 1998;  114 448-455
  PubMedGoogle Scholar
• 10 May A, Gossner L, Günter E. et al . Local treatment of early cancer in short Barrett’s esophagus by means of argon plasma coagulation: initial experience.  Endoscopy. 1999;  31 497-500
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Gossner L, May A, Stolte M. et al . KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett’s esophagus.  Gastrointest Endosc. 1999;  49 8-12
  CrossrefPubMedGoogle Scholar
• 12 Hamilton S R, Aaltonen L A (eds). Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours. Lyon; IARC Press 2000
  Google Scholar
• 13 Overholt B J, Panjehpour M, Halberg D L. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results.  Gastrointest Endosc. 2003;  58 183-188
  CrossrefPubMedGoogle Scholar
• 14 Sharma P. Controversies in Barrett’s esophagus: management of high-grade dysplasia.  Semin Gastrointest Dis. 2001;  12 26-32
  PubMedGoogle Scholar
• 15 Weston A P, Sharma P, Topalovski M. et al . A. Long-term follow-up of Barrett’s high-grade dysplasia.  Am J Gastroenterol. 2000;  95 1888-1893
  CrossrefPubMedGoogle Scholar
• 16 Reid B J, Levine D S, Longton G. et al . Predictors of progression to cancer in Barrett’s esophagus: baseline history and flow cytometry identify low- and high-risk patient subsets.  Am J Gastroenterol. 2000;  95 1669-1676
  PubMedGoogle Scholar
• 17 Schnell T G, Sontag S J, Chejfec G. et al . Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia.  Gastroenterology. 2001;  120 1607-1619
  CrossrefPubMedGoogle Scholar
• 18 Montgomery E, Goldblum J R, Greenson J K. et al . Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.  Hum Pathol. 2001;  32 379-388
  CrossrefPubMedGoogle Scholar
• 19 May A, Gossner L, Pech O. et al . Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach.  Eur J Gastroenterol Hepatol. 2002;  14 1085-1091
  CrossrefPubMedGoogle Scholar
• 20 Montgomery E, Bronner M P, Goldblum J R. et al . Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.  Hum Pathol. 2001;  32 368-378
  CrossrefPubMedGoogle Scholar
• 21 Buttar N S, Wang K K, Sebo T J. et al . Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma.  Gastroenterology. 2001;  120 1630-1639
  CrossrefPubMedGoogle Scholar
• 22 Dar M S, Goldblum J R, Rice T W. et al . Can extent of high grade dysplasia in Barrett’s oesophagus predict the presence of adenocarcinoma at oesophagectomy?.  Gut. 2003;  52 486-489
  CrossrefPubMedGoogle Scholar
• 23 Wolfsen H C, Woodward T A, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma.  Mayo Clin Proc. 2002;  77 1176-1181
  PubMedGoogle Scholar
• 24 Weston A P, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett’s high grade dysplasia and early adenocarcinoma.  Am J Gastroenterol. 2002;  97 2998-3006
  CrossrefPubMedGoogle Scholar
• 25 Overholt B F, Panjehpour M. Photodynamic therapy for Barrett’s esophagus.  Gastrointest Endosc Clin N Am. 1997;  7 207-220
  PubMedGoogle Scholar
• 26 Overholt B F, Lightdale C J, Wang K. et al .International multicenter, partially blinded, randomized study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POF) for the ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE): results of 24-month follow-up. Paper presented at the 104th Annual Meeting of the American Gastroenterological Association (AGA) conference, Orlando, Florida, 18 - 21 May 2003. 
  Google Scholar
• 27 Ackroyd R, Brown N J, Davis M F, Stephenson T J. et al . Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double-blind randomised, placebo controlled trial.  Gut. 2000;  47 612-617
  CrossrefPubMedGoogle Scholar
• 28 Pech O, Nagy C D, Gossner L, May A, Ell C. et al . Photodynamic therapy of human Barrett's cancer using 5-aminolaevulinic acid-induced portoporphyrin IX: an in-vivo dosimetry study in athymic nude mice.  Eur J Gastroenterol Hepatol. 2002;  14 657-662
  CrossrefPubMedGoogle Scholar

A. Behrens, M. D.

Dr. Horst-Schmidt-Kliniken · Innere Medizin II

Ludwig-Erhard-Straße 100 · 65199 Wiesbaden · Germany

Fax: +49-611-432418

Email: ell.hsk-wiesbaden@arcor.de